 | Up a level |
Koenigsmann, M., Casper, J., Kahl, C., Basara, N., Sayer, H. G., Behre, G., Theurich, S., Christopeit, M., Mohren, M., Reichle, A., Metzner, B., Ganser, A., Stadler, M., Uharek, L., Balleisen, L., Hinke, A., Hinke, R. and Niederwieser, D. (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant., 49 (3). S. 410 - 416. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Kraemer, I., Stilgenbauer, S., Dietrich, S., Boettcher, S., Bunjes, D. W., Zeis, M., Stadler, M., Bittenbring, J. T., Uharek, L., Scheid, C., Hegenbart, U., Ho, A., Anthony, D., Hallek, M., Kneba, M., Schmitz, N., Doehner, H. and Dreger, P. (2017). Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial. Bone Marrow Transplant., 52. S. S424 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365